Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance

被引:6
|
作者
Urushihara, Hisashi [1 ,2 ]
Kikuchi, Nobutaka
Yamada, Mayumi
Yoshiki, Fumito
Miyauchi, Akimitsu
机构
[1] Eli Lilly Japan KK, Surveillance & Epidemiol, Global Patient Safety Japan, Qual & Patient Safety,Chuo Ku, Kobe, Hyogo 6510086, Japan
[2] Kyoto Univ, Dept Pharmacoepidemiol, Grad Sch Med & Publ Hlth, Kyoto, Japan
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2009年 / 16卷 / 05期
关键词
Raloxifene; Stroke risk; Postmenopausal osteoporosis; Japanese women; Postmarketing surveillance; BREAST-CANCER; CARDIOVASCULAR EVENTS; OUTCOMES;
D O I
10.1097/gme.0b013e3181a15622
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The aim of this study was to assess whether the risks of stroke and stroke death in Japanese postmenopausal women with osteoporosis exposed to raloxifene increased in comparison with those of the general Japanese female population. Methods: Safety data associated with use of raloxifene were collected in observational settings from 6,970 women with a median follow-up period of 366 days on postmarketing surveillance conducted in Japan. The stroke incidences in raloxifene-treated women were compared with population stroke rates derived from epidemiology studies conducted at three distinct locations in Japan, yielding standardized morbidity ratios for stroke for the purpose of stroke risk assessment. Results: Exposure to raloxifene totaled 7,474 patient-years and 23 stroke cases were reported, including 4 fatal cases. Multiple stroke risk factors were present in three of four women with fatal outcome. The standardized stroke morbidity ratios in raloxifene-treated women versus women from the three reference regions, including Akita Prefecture, Takashima town in Shiga Prefecture, and Okinawa Prefecture, were 0.68 (95% CI, 0.45-1.02), 0.54 (95% CI, 0.35-0.83), and 0.82 (95% CI, 0.54-1.24), respectively. Conclusions: In this initial interim analysis, there seems to be no significant increased risk of stroke among Japanese women with I year of raloxifene use in comparison to Japanese epidemiological data. An increased risk of fatal stroke in the treatment population was indeterminable because of the small number of observed fatal cases. However, ongoing safety monitoring of stroke risk among raloxifene women will continue.
引用
收藏
页码:971 / 977
页数:7
相关论文
共 50 条
  • [1] Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study
    Takeuchi, Yasuhiro
    Hamaya, Etsuro
    Taketsuna, Masanori
    Sowa, Hideaki
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2015, 22 (10): : 1134 - 1137
  • [2] Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study
    Yoh, Kousei
    Hamaya, Etsuro
    Urushihara, Hisashi
    Iikuni, Noriko
    Yamamoto, Takanori
    Taketsuna, Masanori
    Miyauchi, Akimitsu
    Sowa, Hideaki
    Tanaka, Kiyoshi
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (11) : 1757 - 1766
  • [3] Effect of raloxifene hydrochloride on postmenopausal Japanese women with osteoporosis.
    Morii, H
    Orimo, H
    Taketani, Y
    Ishii, J
    Inoue, T
    Fujita, T
    Ohashi, Y
    Huster, WJ
    Lakshmanan, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : T588 - T588
  • [4] Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study
    Ohta, Hiroaki
    Hamaya, Etsuro
    Taketsuna, Masanori
    Sowa, Hideaki
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (01) : 85 - 94
  • [5] Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
    Itsuo Gorai
    Yaku Tanaka
    Shin Hattori
    Yasuhisa Iwaoki
    Journal of Bone and Mineral Metabolism, 2010, 28 : 176 - 184
  • [6] Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
    Gorai, Itsuo
    Tanaka, Yaku
    Hattori, Shin
    Iwaoki, Yasuhisa
    JOURNAL OF BONE AND MINERAL METABOLISM, 2010, 28 (02) : 176 - 184
  • [7] Responsiveness of the Japanese Osteoporosis Quality of Life Questionnaire to Raloxifene Treatment in Women with Postmenopausal Osteoporosis
    Yoh, Kousei
    Hamaya, Etsuro
    Taketsuna, Masanori
    Urushihara, Hisashi
    Tanaka, Kiyoshi
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [8] Assessment of Adherence to Treatment of Osteoporosis with Raloxifene and/or Alfacalcidol in Postmenopausal Japanese Women.
    Gorai, I.
    Tanaka, Y.
    Hattsutori, S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S471 - S471
  • [9] Raloxifene for Osteoporosis in Postmenopausal Women with Rheumatic Diseases
    Lee, Won Seok
    Choi, Yun Jung
    Cheon, Yun-Hong
    Hong, Myong-Joo
    Lee, Chang-Hoon
    Lee, Myeung Su
    Lee, Sang-Il
    Yoo, Wan-Hee
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S984 - S984
  • [10] Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis
    Sanad, Z.
    Ellakwa, H.
    Desouky, B.
    CLIMACTERIC, 2011, 14 (03) : 369 - 377